

# **Exhibit A**

Defendants' Supplement to Filed Exhibit List

## DEFENDANTS' SUPPLEMENT TO FILED EXHIBIT LIST

Case # **2:16-cv-02525-MMD-NJK**Caption: Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA, Inc., et al.**Exhibits for:** Defendants Hikma Pharmaceuticals USA, Inc.; Hikma Pharmaceuticals International Limited; Dr. Reddy's Laboratories, Inc.; and Dr. Reddy's Laboratories, Ltd.

Date Marked	Date Admitted	Number	Witness	Description
		3000		Amarin Open Payment Database (2018)
		3001		Amarin Open Payment Database (2017)
		3002		Amarin Open Payment Database (2016)
		3003		Amarin Open Payment Database (2015)
		3004		Amarin Open Payment Database (2014)
		3005		Amarin Open Payment Database (2013)

Date Marked	Date Admitted	Number	Witness	Description
		3006		Toth Compensation Summary Exhibit
		3007		Lipitor Label 2007
		3008		Toth 2014 Article
		3009		Endocrinology Advisor_Article_2018_Toth Comments
		3010		Prevalence of US adults with TGs_2019
		3011		High TGS are Associated Toth 2018
		3012		P739 TGs 150 and above associated with an increased risk Toth
		3013		HTG in statin treated US adults Toth
		3014		HTG is associated with increased risk

Date Marked	Date Admitted	Number	Witness	Description
				Toth
		3015		Long-term statin persistence Toth
		3016		Crestor 2007 label
		3017		OpenPayment Steps
		3018		Audits and Penalties CMS
		3019		Efficacy and Safety of a New HMG-CoA Reductase Inhibitor
		3020		Toth-Drug Treatment of Hyperlipidaemia